Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome P450 7A1 (CYP7A1), also known as cholesterol 7-alpha-hydroxylase, is a liver-specific microsomal enzyme that catalyzes the rate-limiting step in the classic pathway of bile acid synthesis from cholesterol. By converting cholesterol into 7-alpha-hydroxycholesterol, CYP7A1 plays a critical role in maintaining systemic cholesterol homeostasis and represents the primary pathway for cholesterol elimination from the body. Dysregulation or genetic deficiency of CYP7A1 is strongly associated with hypercholesterolemia, premature gallstone disease, nonalcoholic fatty liver disease (NAFLD), and an increased risk of coronary artery disease. While there are few direct pharmacological inhibitors or activators of CYP7A1 in clinical use, its activity is highly regulated by feedback mechanisms involving nuclear receptors like the farnesoid X receptor (FXR) and the pregnane X receptor (PXR). Consequently, drugs such as FXR agonists (e.g., obeticholic acid), bile acid sequestrants (e.g., cholestyramine), and ASBT inhibitors (e.g., linerixibat) are used to indirectly modulate CYP7A1 expression and activity to treat lipid and cholestatic disorders.
Drugs targeting or modulating CYP7A1 typically act indirectly. This includes farnesoid X receptor (FXR) agonists that repress CYP7A1 expression, bile acid sequestrants and ASBT inhibitors that relieve feedback inhibition to upregulate CYP7A1, and PXR agonists that downregulate its transcription. Direct enzymatic inhibitors are primarily experimental.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome P450 7A1 (CYP7A1) (CYP7A1).